ImmuCell Corporation

NASDAQ: ICCCHealthcare / Biotechnology / USA
5.55-0.2500-4.31%Vol 4 1011Y Perf -18.26%
Aug 23rd, 2019 15:39
BID5.50 ASK5.85
Open5.75 Previous Close5.80
Pre-Market- After-Trading-
 - -%  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potencial %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★★+     55.85
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
★★     45.66
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)40 
Earnings Rating
Neutral
Price Range Ratio 52wk %
1.32 
Earnings Date
12th Aug 2019

Today's Price Range

5.505.75

52wk Range

5.509.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.48%
1 Month
-11.06%
3 Months
-7.50%
6 Months
-23.87%
1 Year
-18.26%
3 Years
-22.92%
5 Years
16.84%
10 Years
107.87%

Name / TickerPriceChg.Chg.%
ICCC5.55-0.2500-4.31
AAPL202.64-9.8200-4.62
GOOG1 151.29-38.2400-3.21
MSFT133.39-4.3900-3.19
XOM67.49-2.0800-2.99
WFC44.42-1.2000-2.63
JNJ127.73-3.5400-2.70
FB177.75-4.2900-2.36
GE7.97-0.2200-2.69
JPM106.02-2.7000-2.48
Earnings HistoryEstimateReportedSurprise %
Q02 2016-0.00-
Q01 2016-0.11-
Q04 2015-0.09-
Q03 2015-0.11-
Q02 2015-0.03-
Q01 2015-0.15-
Q04 2014-0.04-
Q03 2014-0.00-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume4 101
Shares Outstanding (in ths.)7 210
Trades Count0
Dollar Volume0
Avg. Volume7 460
Avg. Weekly Volume2 280
Avg. Monthly Volume3 290
Avg. Quarterly Volume5 784
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Rating---

ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies.

CEO: Micheal F. Brigham

Teplephone: +1 207 878-2770

Address: 56 Evergreen Drive, Portland 04103, ME, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

Bearish Bullish

86%14%

News